Neuropharmacology of New psychoactive substances (NPS): Focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants

Frontiers in Neuroscience

Volumn 10, Issue APR, 2016, Pages

  Miliano, Cristina ^a   Serpelloni, Giovanni ^b   Rimondo, Claudia ^c   Mereu, Maddalena ^d   Marti, Matteo ^e   De Luca, Maria Antonietta ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

Author keywords

Cannabinoids; JWH 018; Novel psychoactive substances; NPS; Psychostimulants; Spice

Indexed keywords

3 (1 NAPHTHOYL) 1 PENTYLINDOLE; 3,4 METHYLENEDIOXYAMPHETAMINE DERIVATIVE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (1,1 DIMETHYLHEPTYL) 2 (3 HYDROXY 7 HYDROXYMETHYLDECAHYDRO 1 NAPHTHYL)PHENOL; AMPHETAMINE; CANNABINOID; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID RECEPTOR AGONIST; CANNABIS; CATHINONE; CYCLOHEXYLAMINE DERIVATIVE; DEXANABINOL; DOPAMINE; DRONABINOL; ILLICIT DRUG; METHAMPHETAMINE; METHCATHINONE; NEW DRUG; PHENETHYLAMINE DERIVATIVE; PIPERAZINE DERIVATIVE; PSYCHOTROPIC AGENT; TRYPTAMINE DERIVATIVE;

COGNITIVE DEFECT; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; EMOTIONAL DISORDER; HUMAN; INCIDENCE; NEUROCHEMISTRY; NEUROPHARMACOLOGY; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS SHELL; REINFORCEMENT; REVIEW; REWARD; SIGNAL TRANSDUCTION; TREND STUDY;

EID: 84966425272     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2016.00153     Document Type: Review

References (193)

1. Aarde, S. M., Creehan, K. M., Vandewater, S. A., Dickerson, T. J., and Taffe, M. A. (2015). In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3, 4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats. Psychopharmacology (Berl.) 232, 3045-3055. doi: 10.1007/s00213-015-3944-8.
2. Aarde, S. M., Huang, P. K., Creehan, K. M., Dickerson, T. J., and Taffe, M. A. (2013). The novel recreational drug 3, 4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology 71, 130-140. doi: 10.1016/j.neuropharm.2013.04.003.
3. ACMD (Advisory Council on the Misuse of Drugs) (2009). Review of the ACMD, 2009-Publications-GOV.UK. Available online at: https://www.gov.uk/government/publications/review-of-the-acmd-2009 (Accessed October 29, 2015).
4. ACMD (Advisory Council on the Misuse of Drugs) (2012). Methoxetamine report, 2012-Publications-GOV.UK. Available at: https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012 (Accessed October 29, 2015).
5. ACMD (Advisory Council on the Misuse of Drugs) (2013). Ketamine: A Review of Use and Harm, London.
6. ACMD (Advisory Council on the Misuse of Drugs) (2014). IMSD 2014/ACMD 2014. Available online at: http://imsd-acmd2014.ksme.or.kr/main/(Accessed October 29, 2015).
7. Anneken, J. H., Angoa-Pérez, M., and Kuhn, D. M. (2015). 3, 4-Methylenedioxypyrovalerone prevents while methylone enhances methamphetamine-induced damage to dopamine nerve endings: β-ketoamphetamine modulation of neurotoxicity by the dopamine transporter. J. Neurochem. 133, 211-222. doi: 10.1111/jnc.13048.
8. Antoniou, K., Galanopoulos, A., Vlachou, S., Kourouli, T., Nahmias, V., Thermos, K., et al. (2005). Behavioral pharmacological properties of a novel cannabinoid 1', 1'-dithiolane delta8-THC analog, AMG-3. Behav. Pharmacol. 16, 499-510. doi: 10.1097/00008877-200509000-00024.
9. Araújo, A. M., Carvalho, F., Bastos, M., de, L., Guedes de Pinho, P., and Carvalho, M. (2015). The hallucinogenic world of tryptamines: an updated review. Arch. Toxicol. 89, 1151-1173. doi: 10.1007/s00204-015-1513-x.
10. Atwood, B. K., Huffman, J., Straiker, A., and MacKie, K. (2010). JWH018, a common constituent of "Spice" herbal blends, is a potent and efficacious cannabinoid CB 1 receptor agonist. Br. J. Pharmacol. 160, 585-593. doi: 10.1111/j.1476-5381.2009.00582.x.
11. Atwood, B. K., Lee, D., Straiker, A., Widlanski, T. S., and Mackie, K. (2011). CP47, 497-C8 and JWH073, commonly found in "Spice" herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur. J. Pharmacol. 659, 139-145. doi: 10.1016/j.ejphar.2011.01.066.
12. Baumann, M. H., Clark, R. D., and Rothman, R. B. (2008). Locomotor stimulation produced by 3, 4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. Pharmacol. Biochem. Behav. 90, 208-217. doi: 10.1016/j.pbb.2008.02.018.
13. Baumann, M. H., Ayestas, M. A. Jr., Partilla, J. S., Sink, J. R., Shulgin, A. T., Daley, P. F., et al. (2012). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37, 1192-1203. doi: 10.1038/npp.2011.304.
14. Baumann, M. H., Partilla, J. S., and Lehner, K. R. (2013). Psychoactive "bath salts": Not so soothing. Eur. J. Pharmacol. 698, 1-5. doi: 10.1016/j.ejphar.2012.11.020.
15. Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., Bolzan Mariotti Posocco, F., et al. (2014). 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. Biomed Res. Int. 2014:734749. doi: 10.1155/2014/734749.
16. Besli, G. E., Ikiz, M. A., Yildirim, S., and Saltik, S. (2015). Synthetic cannabinoid abuse in adolescents: a case series. J. Emerg. Med. 49, 644-650. doi: 10.1016/j.jemermed.2015.06.053.
17. Bonano, J. S., Glennon, R. A., De Felice, L. J., Banks, M. L., and Negus, S. S. (2014). Abuse-related and abuse-limiting effects of methcathinone and the synthetic "bath salts" cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats. Psychopharmacology (Berl). 231, 199-207. doi: 10.1007/s00213-013-3223-5.
18. Bossong, M. G., van Berckel, B. N. M., Boellaard, R., Zuurman, L., Schuit, R. C., Windhorst, A. D., et al. (2009). Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34, 759-766. doi: 10.1038/npp.2008.138.
19. Botanas, C. J., de la Peña, J. B., Dela Pena, I. J., Tampus, R., Kim, H. J., Yoon, S. S., et al. (2015). Evaluation of the abuse potential of AM281, a new synthetic cannabinoid CB1 receptor antagonist. Eur. J. Pharmacol. 766, 135-141. doi: 10.1016/j.ejphar.2015.10.004.
20. Brents, L. K., and Prather, P. L. (2014). The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab. Rev. 46, 72-85. doi: 10.3109/03602532.2013.839700.
21. Brents, L. K., Reichard, E. E., Zimmerman, S. M., Moran, J. H., Fantegrossi, W. E., and Prather, P. L. (2011). Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS ONE 6:e21917. doi: 10.1371/journal.pone.0021917.
22. Brewer, T. L., and Collins, M. (2014). A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. J. Spec. Pediatr. Nurs. 19, 119-126. doi: 10.1111/jspn.12057.
23. Brunt, T. M., Poortman, A., Niesink, R. J. M., and van den Brink, W. (2011). Instability of the ecstasy market and a new kid on the block: mephedrone. J. Psychopharmacol. 25, 1543-1547. doi: 10.1177/0269881110378370.
24. Burns, L., Roxburgh, A, Bruno, R., and Van Buskirk, J. (2014). Monitoring drug markets in the Internet age and the evolution of drug monitoring systems in Australia. Drug Test. Anal. 6, 840-845. doi: 10.1002/dta.1613.
25. Carlezon, W. A. Jr., and Chartoff, E. H. (2007). Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat. Protoc. 2, 2987-2995. doi: 10.1038/nprot.2007.441.
26. Chaperon, F., and Thiébot, M. H. (1999). Behavioral effects of cannabinoid agents in animals. Crit. Rev. Neurobiol. 13, 243-281.
27. Chaperon, F., Soubrié, P., Puech, A. J., and Thiébot, M. H. (1998). Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berl) 135, 324-332. doi: 10.1007/s002130050518.
28. Cheer, J. F., Kendall, D. A., and Marsden, C. A. (2000). Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology (Berl). 151, 25-30. doi: 10.1007/s002130000481.
29. Cheer, J. F., Wassum, K. M., Heien, M. L. A. V., Phillips, P. E. M., and Wightman, R. M. (2004). Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J. Neurosci. 24, 4393-4400. doi: 10.1523/JNEUROSCI.0529-04.2004.
30. Chen, J., Marmur, R., Pulles, A., Paredes, W., and Gardner, E. L. (1993). Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient. Brain Res. 621, 65-70. doi: 10.1016/0006-8993(93)90298-2.
31. Compton, D. R., Johnson, M. R., Melvin, L. S., and Martin, B. R. (1992). Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J. Pharmacol. Exp. Ther. 260, 201-209.
32. Coppola, M., and Mondola, R. (2012). Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as "bath salts" or "plant food." Toxicol. Lett. 211, 144-149. doi: 10.1016/j.toxlet.2012.03.009.
33. Corazza, O., Schifano, F., Farre, M., Deluca, P., Davey, Z., Torrens, M., et al. (2011). Designer drugs on the internet: a phenomenon out-of-control? the emergence ofhallucinogenic drug Bromo-Dragonfly. Curr. Clin. Pharmacol. 6, 125-129. doi: 10.2174/157488411796151129.
34. Corazza, O., Valeriani, G., Bersani, F. S., Corkery, J., Martinotti, G., Bersani, G., et al. (2014). "Spice, " "kryptonite, " "black mamba": an overview of brand names and marketing strategies of novel psychoactive substances on the web. J. Psychoactive Drugs 46, 287-294. doi: 10.1080/02791072.2014.944291.
35. Corkery, J. M., Schifano, F., and Ghodse, A. H. (2012). "Mephedrone-related fatalities in the United Kingdom: contextual, clinical and practicalissues, " in Pharmacology, ed L. Gallelli (Rijeka: InTech), 355-380.
36. Corkery, J. M., Elliott, S., Schifano, F., Corazza, O., and Ghodse, A. H. (2013). MDAI (5, 6-methylenedioxy-2-aminoindane; 6, 7-dihydro-5H-cyclopenta[f][1, 3]benzodioxol-6-amine; "sparkle" "mindy") toxicity: a brief overview and update. Hum. Psychopharmacol. Clin. Exp. 28, 345-355. doi: 10.1002/hup.2298.
37. Corkery, J. M., Claridge, H., Loi, B., Goodair, C., and Schifano, F. (2014). Drug Related Deaths in the, UK. NPSAD Annual Report 2013. London: International Centre for Drug Policy; St. George's University of London.
38. Cozzi, N. V., Gopalakrishnan, A., Anderson, L. L., Feih, J. T., Shulgin, A. T., Daley, P. F., et al. (2009). Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J. Neural Transm. 116, 1591-1599. doi: 10.1007/s00702-009-0308-8.
39. Creehan, K. M., Vandewater, S. A., and Taffe, M. A. (2015). Intravenous self-administration of mephedrone, methylone and MDMA in female rats. Neuropharmacology 92, 90-97. doi: 10.1016/j.neuropharm.2015.01.003.
40. Davidson, C., and Ramsey, J. (2011). Desoxypipradrol is more potent than cocaine on evoked dopamine efflux in the nucleus accumbens. J. Psychopharmacol. 26, 1036-1041. doi: 10.1177/0269881111430733.
41. Dawson, P., Opacka-Juffry, J., Moffatt, J. D., Daniju, Y., Dutta, N., Ramsey, J., et al. (2014). The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat. Prog. Neuro Psychopharmacol. Biol. Psychiatry 48, 57-63. doi: 10.1016/j.pnpbp.2013.08.013.
42. De Luca, M. A., Bimpisidis, Z., Melis, M., Marti, M., Caboni, P., Valentini, V., et al. (2015a). Stimulation of in vivo dopamine transmission and intravenous self-administration in rats and mice by JWH-018, a Spice cannabinoid. Neuropharmacology 99, 705-714. doi: 10.1016/j.neuropharm.2015.08.041.
43. De Luca, M. A., Solinas, M., Bimpisidis, Z., Goldberg, S. R., and Di Chiara, G. (2012). Cannabinoid facilitation of behavioral and biochemical hedonic taste responses. Neuropharmacology 63, 161-168. doi: 10.1016/j.neuropharm.2011.10.018.
44. De Luca, M. A., Castelli, M. P., Loi, B., Porcu, A., Martorelli, M., Miliano, C., et al. (2015b). Native CB1 receptor affinity, intrisic activity and accumbens shell dopamine stimulant properties of third generation spice/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. Neuropharmacology. 105, 630-638. doi: 10.1016/j.neuropharm.2015.11.017.
45. Dean, B. V., Stellpflug, S. J., Burnett, A. M., and Engebretsen, K. M. (2013). 2C or not 2C: phenethylamine designer drug review. J. Med. Toxicol. 9, 172-178. doi: 10.1007/s13181-013-0295-x.
46. Deluca, P., Davey, Z., Corazza, O., Di Furia, L., Farre, M., Flesland, L. H., et al. (2012). Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog. Neuro Psychopharmacol. Biol. Psychiatry 39, 221-226. doi: 10.1016/j.pnpbp.2012.07.011.
47. Denooz, R., Vanheugen, J.-C., Frederich, M., de Tullio, P., and Charlier, C. (2013). Identification and structural elucidation of four cannabimimetic compounds (RCS-4, AM-2201, JWH-203 and JWH-210) in seized products. J. Anal. Toxicol. 37, 56-63. doi: 10.1093/jat/bks095.
48. Di Chiara, G., Bassareo, V., Fenu, S., De Luca, M. A., Spina, L., Cadoni, C., et al. (2004). Dopamine and drug addiction: The nucleus accumbens shell connection. Neuropharmacology 47, 227-241. doi: 10.1016/j.neuropharm.2004.06.032.
49. Drug Policy Department Italian Presidency of the Council of Ministers (2013a). National Action Plan on New Psychoactive Substances, Rome.
50. Drug Policy Department Italian Presidency of the Council of Ministers (2013b). New Psychoactive Substances. Rome.
51. Drug Policy Department Italian Presidency of the Council of Ministers (2014). Annual Report on Drug. Rome.
52. D'Souza, D. C., Fridberg, D. J., Skosnik, P. D., Williams, A., Roach, B., Singh, N., et al. (2012). Dose-related modulation of event-related potentials to novel and target stimuli by intravenous delta9-THC in humans. Neuropsychopharmacology 37, 1632-1646. doi: 10.1038/npp.2012.8.
53. EMCDDA (European Drug Report) (2014). Trends and Developments. Available online at: http://www.emcdda.europa.eu/publications/edr/trends-developments/2014 (Accessed November 14, 2015).
54. EMCDDA (2009a). Annual Report on the State of the Drugs Problem in Europe. Available online at: http://www.emcdda.europa.eu/publications/annual-report/2009 (Accessed October 29, 2015).
55. EMCDDA (2009b). Thematic Papers. Understanding the "Spice" phenomenon.
56. EMCDDA (European Drug Report) (2015a). Trends and Developments. Available online at: http://www.emcdda.europa.eu/publications/edr/trends-developments/2015 (Accessed November 14, 2015).
57. EMCDDA (New psychoactive substances in Europe) (2015b). An Update from the EU Early Warning System. Available online at: http://www.emcdda.europa.eu/publications/2015/new-psychoactive-substances (Accessed December 14, 2015).
58. Eshleman, A. J., Forster, M. J., Wolfrum, K. M., Johnson, R. A., Janowsky, A., and Gatch, M. B. (2014). Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. Psychopharmacology (Berl.) 231, 875-888. doi: 10.1007/s00213-013-3303-6.
59. Eshleman, A. J., Wolfrum, K. M., Hatfield, M. G., Johnson, R. A., Murphy, K. V., and Janowsky, A. (2013). Substituted methcathinones differ in transporter and receptor interactions. Biochem. Pharmacol. 85, 1803-1815. doi: 10.1016/j.bcp.2013.04.004.
60. Every-Palmer, S. (2011). Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend. 117, 152-157. doi: 10.1016/j.drugalcdep.2011.01.012.
61. Fantegrossi, W. E., Murnane, K. S., and Reissig, C. J. (2008). The behavioral pharmacology of hallucinogens. Biochem. Pharmacol. 75, 17-33. doi: 10.1016/j.bcp.2007.07.018.
62. Fass, J. A., Fass, A. D., and Garcia, A. S. (2012). Synthetic Cathinones (Bath Salts): legal status and patterns of abuse. Ann. Pharmacother. 46, 436-441. doi: 10.1345/aph.1Q628.
63. Fattore, L., and Fratta, W. (2011). Beyond THC: The new generation of cannabinoid designer drugs. Front. Behav. Neurosci. 5:60. doi: 10.3389/fnbeh.2011.00060.
64. Fattore, L., Cossu, G., Martellotta, C. M., and Fratta, W. (2001). Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55, 212-2 in rats. Psychopharmacology (Berl). 156, 410-416. doi: 10.1007/s002130100734.
65. Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, B., and Ruoho, A. E. (2010). NIH Public Access. Science, Vol. 323, 934-937. doi: 10.1126/science.1166127.
66. Fraser, F. (2014). New Psychoactive Substances-Evidence Review, Safer Communities Analytical Unit. Edinburgh: Scottish Government Social Research.
67. Gatch, M. B., and Forster, M. J. (2014). Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of compounds commonly found in K2/Spice. Behav. Pharmacol. 25, 750-757. doi: 10.1097/FBP.0000000000000093.
68. Gatch, M. B., and Forster, M. J. (2015). Δ9-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market. Behav. Pharmacol. 26, 460-468. doi: 10.1097/FBP.0000000000000150.
69. Gatch, M. B., Rutledge, M. A., Carbonaro, T., and Forster, M. J. (2009). Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats. Psychopharmacology (Berl). 204, 715-724. doi: 10.1007/s00213-009-1501-z.
70. Gatch, M. B., Taylor, C. M., and Forster, M. J. (2013). Locomotor stimulant and discriminative stimulus effects of "bath salt" cathinones. Behav. Pharmacol. 24, 437-447. doi: 10.1097/FBP.0b013e328364166d.
71. German, C. L., Fleckenstein, A. E., and Hanson, G. R. (2014). Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci. 97, 2-8. doi: 10.1016/j.lfs.2013.07.023.
72. Glass, M., Dragunow, M., and Faull, R. L. (1997). Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77, 299-318. doi: 10.1016/S0306-4522(96)00428-9.
73. González, D., Ventura, M., Caudevilla, F., Torrens, M., and Farre, M. (2013). Consumption of new psychoactive substances in a Spanish sample of research chemical users. Hum. Psychopharmacol. 28, 332-340. doi: 10.1002/hup.2323.
74. Goodman, J., and Packard, M. G. (2015). The influence of cannabinoids on learning and memory processes of the dorsal striatum. Neurobiol. Learn. Mem. 125, 1-14. doi: 10.1016/j.nlm.2015.06.008.
75. Gregg, R. A., Baumann, M. H., Partilla, J. S., Bonano, J. S., Vouga, A., Tallarida, C. S., et al. (2015). Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats. Br. J. Pharmacol. 172, 883-894. doi: 10.1111/bph.12951.
76. Grim, T. W., Wiebelhaus, J. M., Morales, A. J., Negus, S. S., and Lichtman, A. H. (2015). Effects of acute and repeated dosing of the synthetic cannabinoid CP55, 940 on intracranial self-stimulation in mice. Drug Alcohol Depend. 150, 31-37. doi: 10.1016/j.drugalcdep.2015.01.022.
77. Gunderson, E. W., Haughey, H. M., Ait-Daoud, N., Joshi, A. S., and Hart, C. L. (2012). "Spice" and "K2" Herbal Highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am. J. Addict. 21, 320-326. doi: 10.1111/j.1521-0391.2012.00240.x.
78. Hadlock, G. C., Webb, K. M., McFadden, L. M., Chu, P. W., Ellis, J. D., Allen, S. C., et al. (2011). 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J. Pharmacol. Exp. Ther. 339, 530-536. doi: 10.1124/jpet.111.184119.
79. Heimer, L., Zahm, D. S., Churchill, L., Kalivas, P. W., and Wohltmann, C. (1991). Specificity in the projection patterns of accumbal core and shell in the rat. Neuroscience 41, 89-125. doi: 10.1016/0306-4522(91)90202-Y.
80. Helander, A., Beck, O., Hägerkvist, R., and Hultén, P. (2013). Identification of novel psychoactive drug use in Sweden based on laboratory analysis-initial experiences from the STRIDA project. Scand. J. Clin. Lab Invest. 73, 400-406. doi: 10.3109/00365513.2013.793817.
81. Helander, A., Bäckberg, M., Hultén, P., Al-Saffar, Y., and Beck, O. (2014). Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project. Forensic Sci. Int. 243, 23-29. doi: 10.1016/j.forsciint.2014.02.022.
82. Herkenham, M., Lynn, A. B., Johnson, M. R., Melvin, L. S., de Costa, B. R., and Rice, K. C. (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563-583.
83. Hermanns-Clausen, M., Kneisel, S., Szabo, B., and Auwärter, V. (2013). Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108, 534-544. doi: 10.1111/j.1360-0443.2012.04078.x.
84. Hilário, M. R., Clouse, E., Yin, H. H., and Costa, R. M. (2007). Endocannabinoid signaling is critical for habit formation. Front. Integr. Neurosci. 1:6. doi: 10.3389/neuro.07.006.2007.
85. Hohmann, N., Mikus, G., and Czock, D. (2014). Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals. Dtsch. Arztebl. Int. 111, 139-147. doi: 10.3238/arztebl.2014.0139.
86. Hondebrink, L., Nugteren-van Lonkhuyzen, J. J., Van Der Gouwe, D., and Brunt, T. M. (2015). Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre. Drug Alcohol Depend. 147, 109-115. doi: 10.1016/j.drugalcdep.2014.11.033.
87. Hwang, J.-Y., Kim, J.-S., Oh, J.-H., Hong, S.-I., Ma, S.-X., Jung, Y.-H., et al. (2015). The new stimulant designer compound pentedrone exhibits rewarding properties and affects dopaminergic activity. Addict. Biol. doi: 10.1111/adb.12299 [Epub ahead of print].
88. IACP (International Association of Chiefs of Police) (2012). The 2012 Annual Report of the Drug Recognition Expert Section, Alexandria, VA.
89. Iversen, L., Gibbons, S., Treble, R., Setola, V., Huang, X.-P., and Roth, B. L. (2013). Neurochemical profiles of some novel psychoactive substances. Eur. J. Pharmacol. 700, 147-151. doi: 10.1016/j.ejphar.2012.12.006.
90. Iversen, L., White, M., and Treble, R. (2014). Designer psychostimulants: pharmacology and differences. Neuropharmacology 87, 59-65. doi: 10.1016/j.neuropharm.2014.01.015.
91. Johnston, L. D., O'Malley, P. M., Bachman, J. G., and Schulenberg, J. E. (2013). Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings. Bethesda, MD: National Institute on Drug Abuse, 2013. Available online at www.monitoringthefuture.org.
92. Justinova, Z., Tanda, G., Munzar, P., and Goldberg, S. R. (2004). The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology (Berl). 173, 186-194. doi: 10.1007/s00213-003-1693-6.
93. Karila, L., Megarbane, B., Cottencin, O., and Lejoyeux, M. (2015). Synthetic cathinones: a new public health problem. Curr. Neuropharmacol. 13, 12-20. doi: 10.2174/1570159X13666141210224137.
94. Karlsson, L., Andersson, M., Kronstrand, R., and Kugelberg, F. C. (2014). Mephedrone, Methylone and 3, 4-Methylenedioxypyrovalerone (MDPV) induce conditioned place preference in mice. Basic Clin. Pharmacol. Toxicol. 115, 411-416. doi: 10.1111/bcpt.12253.
95. Kehr, J., Ichinose, F., Yoshitake, S., Goiny, M., Sievertsson, T., Nyberg, F., et al. (2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br. J. Pharmacol. 164, 1949-1958. doi: 10.1111/j.1476-5381.2011.01499.x.
96. Kelly, J. P. (2011). Cathinone derivatives: A review of their chemistry, pharmacology and toxicology. Drug Test. Anal. 3, 439-453. doi: 10.1002/dta.313.
97. Kersten, B. P., and McLaughlin, M. E. (2015). Toxicology and management of novel psychoactive drugs. J. Pharm. Pract. 28, 50-65. doi: 10.1177/0897190014544814.
98. Khullar, V., Jain, A., and Sattari, M. (2014). Emergence of New Classes of Recreational Drugs-Synthetic Cannabinoids and Cathinones. J. Gen. Intern. Med. 29, 1200-1204. doi: 10.1007/s11606-014-2802-4.
99. Kikura-Hanajiri, R., Kawamura, N. U. M., and Goda, Y. (2014). Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan. Drug Test. Anal. 6, 832-839. doi: 10.1002/dta.1584.
100. Koob, G. F., and Volkow, N. D. (2010). Neurocircuitry of addiction. Neuropsychopharmacology 35, 217-238. doi: 10.1038/npp.2009.110.
101. Kronstrand, R., Brinkhagen, L., Birath-Karlsson, C., Roman, M., and Josefsson, M. (2014). LC-QTOF-MS as a superior strategy to immunoassay for the comprehensive analysis of synthetic cannabinoids in urine. Anal. Bioanal. Chem. 406, 3599-3609. doi: 10.1007/s00216-013-7574-x.
102. Kwilasz, A. J., and Negus, S. S. (2012). Dissociable effects of the cannabinoid receptor agonists Δ9-tetrahydrocannabinol and CP55940 on pain-stimulated versus pain-depressed behavior in rats. J. Pharmacol. Exp. Ther. 343, 389-400. doi: 10.1124/jpet.112.197780.
103. Kyriakou, C., Marinelli, E., Frati, P., Santurro, A., Afxentiou, M., Zaami, S., et al. (2015). NBOMe: new potent hallucinogens-pharmacology, analytical methods, toxicities, fatalities: a review. Eur. Rev. Med. Pharmacol. Sci. 19, 3270-3281.
104. Le Roux, G., Bruneau, C., Lelièvre, B., Deguigne, M. B., Turcant, A., Harry, P., et al. (2015). Recreational phenethylamine poisonings reported to a French poison control center. Drug Alcohol Depend. 154, 46-53. doi: 10.1016/j.drugalcdep.2015.05.048.
105. Lecca, D., Cacciapaglia, F., Valentini, V., and Di Chiara, G. (2006). Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55, 212-2 self-administration. Psychopharmacology (Berl). 188, 63-74. doi: 10.1007/s00213-006-0475-3.
106. Liechti, M. (2015). Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med. Wkly. 145:w14043. doi: 10.4414/smw.2015.14043.
107. Lisek, R., Xu, W., Yuvasheva, E., Chiu, Y.-T., Reitz, A. B., Liu-Chen, L.-Y., et al. (2012). Mephedrone ("bath salt") elicits conditioned place preference and dopamine-sensitive motor activation. Drug Alcohol Depend. 126, 257-262. doi: 10.1016/j.drugalcdep.2012.04.021.
108. Loi, B., Corkery, J. M., Claridge, H., Goodair, C., Chiappini, S., Gimeno Clemente, C., et al. (2015). Deaths of individuals aged 16-24 years in the UK after usingmephedrone. Hum. Psychopharmacol. 30, 225-232. doi: 10.1002/hup.2423.
109. Lessin, A. W., Long, R. F., and Parkes, M. W. (1965). Central Stimulant Actions of Alpha-Alkyl Substituted Tryptamines in Mice. Br. J. Pharmacol. Chemother. 24, 49-67. doi: 10.1111/j.1476-5381.1965.tb02079.x.
110. López-Arnau, R., Martínez-Clemente, J., Pubill, D., Escubedo, E., and Camarasa, J. (2012). Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br. J. Pharmacol. 167, 407-420. doi: 10.1111/j.1476-5381.2012.01998.x.
111. Lupica, C. R., and Riegel, A. C. (2005). Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 48, 1105-1116. doi: 10.1016/j.neuropharm.2005.03.016.
112. Maas, A., Wippich, C., Madea, B., and Hess, C. (2015). Driving under the influence of synthetic phenethylamines: a case series. Int. J. Legal Med. 129, 997-1003. doi: 10.1007/s00414-015-1150-1.
113. Macfarlane, V., and Christie, G. (2015). Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev. 34, 147-153. doi: 10.1111/dar.12225.
114. Marshell, R., Kearney-Ramos, T., Brents, L. K., Hyatt, W. S., Tai, S., Prather, P. L., et al. (2014). In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ(9)-THC in mice: inhalation versus intraperitoneal injection. Pharmacol. Biochem. Behav. 124, 40-47. doi: 10.1016/j.pbb.2014.05.010.
115. Martellotta, M. C., Cossu, G., Fattore, L., Gessa, G. L., and Fratta, W. (1998). Self-administration of the cannabinoid receptor agonist WIN 55, 212-2 in drug-naive mice. Neuroscience 85, 327-330. doi: 10.1016/S0306-4522(98)00052-9.
116. Martinotti, G., Lupi, M., Carlucci, L., Cinosi, E., Santacroce, R., Acciavatti, T., et al. (2015). Novel psychoactive substances: use and knowledge among adolescents and young adults in urban and rural areas. Hum Psychopharmacol. 30, 295-301. doi: 10.1002/hup.2486.
117. Marusich, J. A., Grant, K. R., Blough, B. E., and Wiley, J. L. (2012). Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice. Neurotoxicology 33, 1305-1313. doi: 10.1016/j.neuro.2012.08.003.
118. Mátyás, F., Urbán, G. M., Watanabe, M., Mackie, K., Zimmer, A., Freund, T. F., et al. (2008). Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology 54, 95-107. doi: 10.1016/j.neuropharm.2007.05.028.
119. Mavrikaki, M., Markaki, E., Nomikos, G. G., and Panagis, G. (2010). Chronic WIN55, 212-2 elicits sustained and conditioned increases in intracranial self-stimulation thresholds in the rat. Behav. Brain Res. 209, 114-118. doi: 10.1016/j.bbr.2010.01.024.
120. Maxwell, J. C. (2014). Psychoactive substances-some new, some old: a scan of the situation in the U.S. Drug Alcohol Depend. 134, 71-77. doi: 10.1016/j.drugalcdep.2013.09.011.
121. Melis, M., Sagheddu, C., De Felice, M., Casti, A., Madeddu, C., Spiga, S., et al. (2014). Enhanced endocannabinoid-mediated modulation of rostromedial tegmental nucleus drive onto dopamine neurons in sardinian alcohol-preferring rats. J. Neurosci. 34, 12716-12724. doi: 10.1523/JNEUROSCI.1844-14.2014.
122. Meririnne, E., Kajos, M., Kankaanpää, A., and Seppälä, T. (2006). Rewarding properties of 1-benzylpiperazine, a new drug of abuse, in rats. Basic Clin. Pharmacol. Toxicol. 98, 346-350. doi: 10.1111/j.1742-7843.2006.pto_243.x.
123. Mills, B., Yepes, A., and Nugent, K. (2015). Synthetic Cannabinoids. Am. J. Med. Sci. 350, 59-62. doi: 10.1097/MAJ.0000000000000466.
124. Monteiro, M. S., Bastos, M. D. L., Guedes de Pinho, P., and Carvalho, M. (2013). Update on 1-benzylpiperazine (BZP) party pills. Arch. Toxicol. 87, 929-947. doi: 10.1007/s00204-013-1057-x.
125. Motbey, C. P., Clemens, K. J., Apetz, N., Winstock, A. R., Ramsey, J., Li, K. M., et al. (2013). High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: neural consequences and comparison with methamphetamine. J. Psychopharmacol. 27, 823-836. doi: 10.1177/0269881113490325.
126. National Drug Intelligence Center (NDIC) (2011). National Drug Treat Assessment.
127. Negus, S. S., and Miller, L. L. (2014). Intracranial self-stimulation to evaluate abuse potential of drugs. Pharmacol. Rev. 66, 869-917. doi: 10.1124/pr.112.007419.
128. Nelson, M. E., Bryant, S. M., and Aks, S. E. (2014). Emerging drugs of abuse. Dis. Mon. 60, 110-132. doi: 10.1016/j.disamonth.2014.01.001.
129. Nichols, D. E. (2004). Hallucinogens. Pharmacol. Ther. 101, 131-181. doi: 10.1016/j.pharmthera.2003.11.002.
130. NIDA (National Institute on Drug Abuse) (2012). Monitoring the Future 2012 Survey Results. Available online at: https://www.drugabuse.gov/related-topics/trends-statistics/infographics/monitoring-future-2012-survey-results (Accessed October 29, 2015).
131. Nishimura, M., and Sato, K. (1999). Ketamine stereoselectively inhibits rat dopamine transporter. Neurosci. Lett. 274, 131-134. doi: 10.1016/S0304-3940(99)00688-6.
132. Ossato, A., Canazza, I., Trapella, C., Vincenzi, F., De Luca, M. A., Rimondo, C., et al. (2016). Effect of JWH-250, JWH-073 and their interaction on "tetrad, " sensorimotor, neurological and neurochemical responses in mice. Prog Neuropsychopharmacol. Biol Psychiatry. 15, 31-50. doi: 10.1016/j.pnpbp.2016.01.007.
133. Paillet-Loilier, M., Cesbron, A., Le Boisselier, R., Bourgine, J., and Debruyne, D. (2014). Emerging drugs of abuse: current perspectives on substituted cathinones. Subst. Abuse Rehabil. 5, 37-52. doi: 10.2147/SAR.S37257.
134. Palamar, J. J., Martins, S. S., Su, M. K., and Ompad, D. C. (2015). Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting. Drug Alcohol Depend. 156, 112-119. doi: 10.1016/j.drugalcdep.2015.08.028.
135. Panagis, G., Mackey, B., and Vlachou, S. (2014). Cannabinoid regulation of brain reward processing with an emphasis on the role of CB1 receptors: a step Back into the Future. Front. Psychiatry 5:92. doi: 10.3389/fpsyt.2014.00092.
136. Papanti, D., Schifano, F., Botteon, G., Bertossi, F., Mannix, J., Vidoni, D., et al. (2013). "Spiceophrenia": a systematic overview of "spice"-related psychopathological issues and a case report. Hum. Psychopharmacol. 28, 379-389. doi: 10.1002/hup.2312.
137. Paus, T. (2005). Mapping brain maturation and cognitive development during adolescence. TrendsCogn Sci. 9, 60-68. doi: 10.1016/j.tics.2004.12.008.
138. Prosser, J. M., and Nelson, L. S. (2012). The toxicology of bath salts: a review of synthetic cathinones. J. Med. Toxicol. 8, 33-42. doi: 10.1007/s13181-011-0193-z.
139. Sanders, B., Lankenau, S. E., Bloom, J. J., and Hathazi, D. (2008). "Research chemicals": tryptamine and phenethylamine use among high-risk youth. Subst. Use Misuse. 43, 389-402. doi: 10.1080/00952990701202970.
140. Santacroce, R., Corazza, O., Martinotti, G., Bersani, F. S., Valeriani, G., and Di Giannantonio, M. (2015). Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products. Hum. Psychopharmacol. 30, 265-271. doi: 10.1002/hup.2410.
141. Sañudo-Peña, M. C., Tsou, K., Delay, E. R., Hohman, A. G., Force, M., and Walker, J. M. (1997). Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci. Lett. 223, 125-128.
142. Schifano, F. (2013). "Novel psychoactive substances also known as 'legal highs', " in Annual Report of the Chief MedicalOfficer. Public Mental Health Priorities: Investing in the Evidence, ed S. C Davies (London: Department of Health), 259.
143. Schifano, F., Corkery, J. M., and Cuffolo, G. (2007). Smokable ("ice, " "crystal meth") and non smokable amphetamine-type stimulants: Clinical pharmacological and epidemiological issues, with special reference to the UK. Ann. Ist Super. Sanita 43, 110-115.
144. Schifano, F., Corkery, J., Naidoo, V., Oyefeso, A., and Ghodse, H. (2010). Overview ofamphetamine-type stimulant mortality data-UK, 1997-2007. Neuropsychobiology 61, 122-130. doi: 10.1159/000279302.
145. Schifano, F., Corkery, J., and Ghodse, A. H. (2012). Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone;'meow meow') in the UK. J. Clin. Psychopharmacol. 32, 7104. doi: 10.1097/JCP.0b013e318266c70c.
146. Schifano, F., Orsolini, L., Duccio Papanti, G., and Corkery, J. M. (2015). Novel psychoactive substances of interest for psychiatry. World Psychiatry 14, 15-26. doi: 10.1002/wps.20174.
147. Schindler, C. W., Thorndike, E. B., Goldberg, S. R., Lehner, K. R., Cozzi, N. V., Brandt, S. D., et al. (2015). Reinforcing and neurochemical effects of the "bath salts" constituents 3, 4-methylenedioxypyrovalerone (MDPV) and 3, 4-methylenedioxy-N-methylcathinone (methylone) in male rats. Psychopharmacology (Berl). doi: 10.1007/s00213-015-4057-0. [Epub ahead of print].
148. Seely, K. A., Prather, P. L., James, L. P., and Moran, J. H. (2011). Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol. Interv. 11, 36-51. doi: 10.1124/mi.11.1.6.
149. Seely, K. A., Brents, L. K., Radominska-Pandya, A., Endres, G. W., Keyes, G. S., Moran, J. H., et al. (2012). A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem. Res. Toxicol. 39, 234-243. doi: 10.1021/tx3000472.
150. Sidhpura, N., and Parsons, L. H. (2011). Endocannabinoid-mediated synaptic plasticity and addiction-related behavior. Neuropharmacology 61, 1070-1087. doi: 10.1016/j.neuropharm.2011.05.034.
151. Simmler, L. D., Buser, T. A., Donzelli, M., Schramm, Y., Dieu, L.-H., Huwyler, J., et al. (2013). Pharmacological characterization of designer cathinones in vitro. Br. J. Pharmacol. 168, 458-470. doi: 10.1111/j.1476-5381.2012.02145.x.
152. Simmler, L. D., Rickli, A., Schramm, Y., Hoener, M. C., and Liechti, M. E. (2014). Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochem. Pharmacol. 88, 237-244. doi: 10.1016/j.bcp.2014.01.024.
153. Simonato, P., Corazza, O., Santonastaso, P., Corkery, J., Deluca, P., Davey, Z., et al. (2013). Novel psychoactive substances as a novel challenge for health professionals: results from an Italian survey. Hum. Psychopharmacol. 28, 324-331. doi: 10.1002/hup.2300.
154. Smith, J. P., Sutcliffe, O. B., and Banks, C. E. (2015). An overview of recent developments in the analytical detection of new psychoactive substances (NPSs). Analyst 140, 4932-4948. doi: 10.1039/C5AN00797F.
155. Sogawa, C., Sogawa, N., Tagawa, J., Fujino, A., Ohyama, K., Asanuma, M., et al. (2007). 5-Methoxy-N, N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter. Toxicol. Lett. 170, 75-82. doi: 10.1016/j.toxlet.2007.02.007.
156. Solinas, M., Panlilio, L. V., Justinova, Z., Yasar, S., and Goldberg, S. R. (2006). Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat Protoc. 1, 1194-1206. doi: 10.1038/nprot.2006.167.
157. Spaderna, M., Addy, P. H., and D'souza, D. C. (2013). Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl) 228, 525-540. doi: 10.1007/s00213-013-3188-4.
158. Sussman, S., Skara, S., and Ames, S. L. (2008). Substance abuse among adolescents. Substance Use Misuse 43, 1802-1828. doi: 10.1080/10826080802297302.
159. Tanda, G., Pontieri, F. E., and Di Chiara, G. (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276, 2048-2050. doi: 10.1126/science.276.5321.2048.
160. Tanda, G., Munzar, P., and Goldberg, S. R. (2000). Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat. Neurosci. 3, 1073-1074. doi: 10.1038/80577.
161. Teixeira-Gomes, A., Costa, V. M., Feio-Azevedo, R., de Lourdes Bastos, M., Carvalho, F., and Capela, J. P. S. (2014). The neurotoxicity of amphetamines during the adolescent period. Int. J. Dev. Neurosci. 41, 1-18. doi: 10.1016/j.ijdevneu.2014.12.001.
162. Thomas, S., Bliss, S., and Malik, M. (2012). Suicidal ideation and self-harm following K2 use. J. Okla. State Med. Assoc. 105, 430-433.
163. Tittarelli, R., Mannocchi, G., Pantano, F., and Romolo, F. S. (2015). Recreational use, analysis and toxicity of tryptamines. Curr. Neuropharmacol. 13, 26-46. doi: 10.2174/1570159X13666141210222409.
164. Vigolo, A., Ossato, A., Trapella, C., Vincenzi, F., Rimondo, C., Seri, C., et al. (2015). Novel halogenated derivates of JWH-018: behavioral and binding studies in mice. Neuropharmacology 95, 68-82. doi: 10.1016/j.neuropharm.2015.02.008.
165. UNODC (2013). Global Smart Update 2013. Vienna.
166. UNODC (2014a). Early Warning Advisory on NPS. Vienna.
167. UNODC (2014b). World Drugs Report. Vienna.
168. UNODC (2015). The Challenge of Synthetic Drugs in East and South-East Asia and Oceania. Trends and Patterns of Amphetamine-type Stimulants and New Psychoactive Substances. World Drugs Report. Wien: Global SMART Programme.
169. Valente, M. J., Guedes de Pinho, P., de Lourdes Bastos, M., Carvalho, F., and Carvalho, M. (2014). Khat and synthetic cathinones: a review. Arch. Toxicol. 88, 15-45. doi: 10.1007/s00204-013-1163-9.
170. Valjent, E., and Maldonado, R. (2000). A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology 147, 436-438. doi: 10.1007/s002130050013.
171. Van Amsterdam, J., Brunt, T., and van den Brink, W. (2015). The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J. Psychopharmacol. 29, 254-263. doi: 10.1177/0269881114565142.
172. Vlachou, S., Nomikos, G. G., and Panagis, G. (2005). CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat. Psychopharmacology (Berl) 179, 498-508. doi: 10.1007/s00213-004-2050-0.
173. Vlachou, S., Nomikos, G. G., Stephens, D. N., and Panagis, G. (2007). Lack of evidence for appetitive effects of Delta 9-tetrahydrocannabinol in the intracranial self-stimulation and conditioned place preference procedures in rodents. Behav. Pharmacol. 18, 311-319. doi: 10.1097/FBP.0b013e3282186cf2.
174. Volkow, N. D., Fowler, J. S., and Wang, G.-J. (2003). The addicted human brain: insights from imaging studies. J. Clin. Invest. 111, 1444-1451. doi: 10.1172/JCI18533.
175. Völlm, B. A., de Araujo, I. E., Cowen, P. J., Rolls, E. T., Kringelbach, M. L., Smith, K. A., et al. (2004). Methamphetamine activates reward circuitry in drug naïve human subjects. Neuropsychopharmacology 29, 1715-1722. doi: 10.1038/sj.npp.1300481.
176. Wang, X., Dow-Edwards, D., Keller, E., and Hurd, Y. L. (2003). Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience 118, 681-694.
177. Watterson, L. R., Hood, L., Sewalia, K., Tomek, S. E., Yahn, S., Johnson, C. T., et al. (2012). The reinforcing and rewarding effects of methylone, a synthetic cathinone commonly found in "Bath Salts." J. Addict. Res. Ther. pii (Suppl. 9):002. doi: 10.4172/2155-6105.S9-002.
178. Watterson, L. R., Kufahl, P. R., Nemirovsky, N. E., Sewalia, K., Grabenauer, M., Thomas, B. F., et al. (2014). Potent rewarding and reinforcing effects of the synthetic cathinone 3, 4-methylenedioxypyrovalerone (MDPV). Addict. Biol. 19, 165-174. doi: 10.1111/j.1369-1600.2012.00474.x.
179. Wells, D. L., and Ott, C. A. (2011). The "new" marijuana. Ann. Pharmacother. 45, 414-417. doi: 10.1345/aph.1P580.
180. Welter-Luedeke, J., and Maurer, H. H. (2015). New psychoactive substances. Ther. Drug Monit. 38, 4-11. doi: 10.1097/FTD.0000000000000240.
181. Whelpton, R. (2007). Speed, Ecstasy, Ritalin: the science of amphetamines. Br. J. Clin. Pharmacol. 63, 763-763. doi: 10.1111/j.1365-2125.2006.02818.x.
182. Wikström, M., Holmgren, P., and Ahlner, J. (2004). A2 (N-benzylpiperazine) a new drug of abuse in Sweden. J. Anal. Toxicol. 28, 67-70. doi: 10.1093/jat/28.1.67.
183. Wiley, J. L., Marusich, J. A., Martin, B. R., and Huffman, J. W. (2012). 1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice. Drug Alcohol Depend. 123, 148-153. doi: 10.1016/j.drugalcdep.2011.11.001.
184. Wiley, J. L., Marusich, J. A., and Huffman, J. W. (2014). Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci. 97, 55-63. doi: 10.1016/j.lfs.2013.09.011.
185. Winstock, A. R., and Barratt, M. J. (2013). The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum. Psychopharmacol. Clin. Exp. 28, 390-393. doi: 10.1002/hup.2292.
186. Winstock, A., and Schifano, F. (2009). "Disorders relating to the use of ecstasy, other 'party drugs' and khat, " in New Oxford Textbook of Psychiatry eds M. Gelder, N. Andreasen, J. J. Lopez-Ibor, and J. Geddes (Oxford: Oxford University Press), 494-502.
187. Winstock, A. R., Mitcheson, L. R., Deluca, P., Davey, Z., Corazza, O., and Schifano, F. (2011). Mephedrone, new kid for the chop? Addiction 106, 154-161. doi: 10.1111/j.1360-0443.2010.0330.x.
188. Wood, D. M., Heyerdahl, F., Yates, C. B., Dines, A. M., Giraudon, I., and Hovda, K. E. (2014). The european drug emergencies network (Euro-DEN). Clin. Toxicol. (Phila). 52, 239-241. doi: 10.3109/15563650.2014.898771.
189. Wood, D. M., Sedefov, R., Cunningham, A., and Dargan, P. I. (2015). Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin. Toxicol. 53, 85-92. doi: 10.3109/15563650.2015.1004179.
190. Wright, M. J. Jr., Angrish, D., Aarde, S. M., Barlow, D. J., Buczynski, M. W., Creehan, K. M., et al. (2012). Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in wistar and sprague-dawley rats. PLoS ONE 7:e44652. doi: 10.1371/journal.pone.0044652.
191. Zahm, D. S., and Brog, J. S. (1992). On the significance of subterritories in the "accumbens" part of the rat ventral striatum. Neuroscience 50, 751-767. doi: 10.1016/0306-4522(92)90202-D.
192. Zawilska, J. B. (2015). "Legal Highs"-An Emerging Epidemic of Novel Psychoactive Substances. Int. Rev. Neurobiol. 120, 273-300. doi: 10.1016/bs.irn.2015.02.009.
193. Zimmermann, U. S., Winkelmann, P. R., Pilhatsch, M., Nees, J. A., Spanagel, R., and Schulz, K. (2009). Withdrawal phenomena and dependence syndrome after the consumption of "spice gold." Dtsch. Arztebl. Int. 106, 464-467. doi: 10.3238/arztebl.2009.0464.